Albany, NY, Feb. 09, 2018 -- The global e-clinical solution software market is stood at US$3,005 million in 2014. The market is projected to expand at a handsome CAGR of 13.8% during 2014–2020 and reach US$6,515.3 million in 2020.
Exponential Rise of Clinical Trials by Pharmaceutical and Life Sciences Companies to Bolster Demand
The staggering rise in volume of clinical trials and the burgeoning spend on research and development activities by pharmaceutical and life science companies are notable factors driving the demand for e-clinical solution software. The growing digitization of healthcare infrastructure world over is significant contributing to the growth of the market. The rising prevalence of chronic diseases has led to exponential rise in R&D in several developing and developed countries, which is bolstering the demand for e-clinical solutions. Of particular interest are the rise in lifestyle associated diseases and the growing prevalence of genetic disorders in parts of the Middle East and North Africa, which is accentuating the growth of the e-clinical solution software market.
Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2548
The rising prominence of clinical research organizations in the outsourcing of R&D activities of pharmaceutical and life sciences players is aiding in the expansion of the market. With clinical research become increasing complex, this will further bolster the demand. The mounting pressure on pharmaceutical companies to reduce operational cost and expedite time-to-market of various drugs has led them increasingly demand e-clinical solutions to make the most out of their research investment.
Broadly, the various end-users are the pharmaceutical industry, chemical research organizations (CROs), and the healthcare sector. Of these, the pharmaceutical industry is likely to emerge as the leading segment over the forecast period, driven by the widespread uptake of e-clinical solution software. However, over the same period, the CROs is projected to emerge at the dominant pace.
Download PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2548
The various regional segments are Europe, North America, Asia Pacific, and Rest of the World. Of these, North America accounts for the leading market share. The regional market is projected to expand at a CAGR of 12.6% during 2014 - 2020. Meanwhile, Asia Pacific is the most attractive market and anticipated to rise at the leading CAGR during the same period.
Growing Adoption of Cloud-Based Solutions to Unlock Exciting Prospects
The intensifying competition in the e-clinical solution software market has led to the decline in pricing of several e-clinical solutions. This augurs well for the market, especially in developing economies. Several emerging and established players are seeking lucrative avenues in these economies. The extensive demand for e-clinical solution software on web-based model is accentuating the growth of the market. The market is also likely to benefit substantially from the emerging popularity of cloud-based solutions. The marked potential of these solutions to share data and results world over accounts for their attractiveness. The need for converging medical and healthcare data from across an assortment of healthcare platforms at a centralized node is a notable factor boosting the demand for cloud-based solutions.
Buy E-Clinical Solution Software Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=2548<ype=S
Some of the players showcasing prominence in the global e-clinical solution software market are CRF Health Inc., PHT Corp., DATATRAK International Inc., OmniComm Systems Inc., ERT, PAREXEL International Corp., BioClinica, Merge Healthcare Inc., Medidata Solutions Inc., and Oracle Corporation, finds Transparency Market Research (TMR). A number of top players are intensely focused on tapping lucrative avenues from surging investments in clinical researches in the pharmaceuticals and life sciences industries, notably in several countries of the Middle East and North Africa.
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Contact
Nachiket Ghumare
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Research Blog: http://theglobalhealthnews.com/


Samsung Electronics Shares Jump on HBM4 Mass Production Report
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Anta Sports Expands Global Footprint With Strategic Puma Stake
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Washington Post Publisher Will Lewis Steps Down After Layoffs
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



